Reduces risk for heart failure and cardiovascular disease hospitalizations.
Drug able to treat 18,000 people will cost over $300k per year.
Available for prescribing starting January 2020
First approved in 2018 for patients 12 years of age and older.
Originally approved in 1995 for use in adults only.
Administered via a once-daily transdermal patch.
Noteworthy diabetes management products and updates making waves this year.
Consumers should stop use and report any adverse events.
New CGM eliminates fingersticks, introduces new data presentation.
Afamelanotide released through subcutaneous implant.